A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Northwestern scientists said they found pancreatic cancer cells play a trick on a person's immune system by wearing a sugar cloak to disguise themselves as a healthy cell.

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

The PanCAN Patient Services team is here for patients and their loved ones as they navigate clinical trials. Our Case Managers offer personal, one-to-one support at every step of the search and ...

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. With an overall survival rate of around 13%, it’s also one of the deadliest cancers. One reason for this is that ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Treating pancreatic cancer remains one of oncology’s greatest challenges. The disease is often diagnosed at an advanced stage, progresses rapidly, and responds poorly to existing treatments.